Bionomics Past Earnings Performance
Past criteria checks 0/6
Bionomics's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 10.6% annually. Revenues have been declining at an average rate of 33% per year.
Key information
-33.7%
Earnings growth rate
-11.9%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -33.0% |
Return on equity | -88.6% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bionomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -15 | 8 | 9 |
31 Mar 24 | 0 | -18 | 9 | 11 |
31 Dec 23 | 0 | -21 | 7 | 0 |
30 Sep 23 | 0 | -20 | 6 | 0 |
30 Jun 23 | 0 | -21 | 9 | 13 |
31 Mar 23 | 2 | -19 | 7 | 6 |
31 Dec 22 | 4 | -17 | 5 | 0 |
30 Sep 22 | 4 | -15 | 5 | 0 |
30 Jun 22 | 4 | -15 | 5 | 0 |
31 Mar 22 | 2 | -16 | 6 | 0 |
31 Dec 21 | 0 | -16 | 6 | 0 |
30 Sep 21 | 1 | -11 | 5 | 0 |
30 Jun 21 | 1 | -7 | 4 | 0 |
31 Mar 21 | 1 | -3 | 4 | 0 |
31 Dec 20 | 1 | 1 | 4 | 0 |
30 Sep 20 | 2 | -2 | 4 | 0 |
30 Jun 20 | 2 | -4 | 3 | 0 |
31 Dec 19 | 4 | -3 | 4 | 0 |
30 Sep 19 | 5 | -5 | 4 | 0 |
30 Jun 19 | 5 | -7 | 6 | 0 |
31 Mar 19 | 6 | -14 | 8 | 0 |
31 Dec 18 | 5 | -20 | 8 | 0 |
30 Sep 18 | 7 | -19 | 8 | 0 |
30 Jun 18 | 9 | -19 | 8 | 0 |
31 Mar 18 | 15 | -12 | 7 | 0 |
31 Dec 17 | 21 | -5 | 6 | 0 |
30 Sep 17 | 21 | -5 | 6 | 0 |
30 Jun 17 | 21 | -5 | 6 | 0 |
31 Mar 17 | 17 | -9 | 8 | 0 |
31 Dec 16 | 12 | -12 | 9 | 0 |
30 Sep 16 | 14 | -13 | 9 | 0 |
30 Jun 16 | 14 | -12 | 8 | 0 |
31 Mar 16 | 14 | -14 | 8 | 0 |
31 Dec 15 | 13 | -15 | 7 | 0 |
30 Sep 15 | 12 | -13 | 6 | 0 |
30 Jun 15 | 12 | -13 | 7 | 0 |
31 Mar 15 | 17 | -5 | 5 | 0 |
31 Dec 14 | 24 | 4 | 4 | 0 |
30 Sep 14 | 25 | 3 | 4 | 0 |
30 Jun 14 | 25 | 3 | 4 | 0 |
31 Mar 14 | 18 | -4 | 5 | 0 |
31 Dec 13 | 10 | -11 | 5 | 0 |
Quality Earnings: B1N0 is currently unprofitable.
Growing Profit Margin: B1N0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B1N0 is unprofitable, and losses have increased over the past 5 years at a rate of 33.7% per year.
Accelerating Growth: Unable to compare B1N0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B1N0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.4%).
Return on Equity
High ROE: B1N0 has a negative Return on Equity (-88.58%), as it is currently unprofitable.